Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.

Antimicrobial agents and chemotherapy - 1 Nov 2007

van der Lee Manon J, Blenke Audrey A M, Rongen Gerard A, Verwey-van Wissen Corrien P W G M, Koopmans Peter P, Pharo Cristina, Burger David M

Abstract excerpt

Human immunodeficiency virus-infected patients have an increased risk for depression. Despite the high potential for drug-drug interactions, limited data on the combined use of antidepressants and antiretrovirals are available. Theoretically, ritonavir-boosted protease inhibitors may inhibit CYP2...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antidepressive Agents, Second-Generation
Share to Carbamates
Share to Drug Interactions

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Furans

Share to Metabolic Clearance Rate

Share to Organophosphates

Share to Paroxetine

Share to Ritonavir

Source

Open in PubMed Open full text

Identifiers

PMID: 17846135
DOI: 10.1128/AAC.01243-06
PMCID: PMC2151442

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-17846135-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Interaction study of the combined use of paroxetine and fosamprenavir-ritonavir in healthy subjects.PMID 17846135Read ↗

Pharmacokinetic drug-drug interaction study between raltegravir and citalopram.Semantic proximity Read ↗

Effect of fluoxetine on pharmacokinetics of ritonavir.Semantic proximity Read ↗

Fixed combinations of neuroleptics with antidepressants: potential risks and estimation of use.Semantic proximity Read ↗

Minimal Pharmacokinetic Interaction between the Human Immunodeficiency Virus Nonnucleoside Reverse Transcriptase Inhibitor Etravirine and the Integrase Inhibitor Raltegravir in Healthy SubjectsSemantic proximity Read ↗

A pharmacokinetic drug-drug interaction study of venlafaxine and indinavir.Semantic proximity Read ↗

Pharmacokinetics and short-term safety of etravirine in combination with fluconazole or voriconazole in HIV-negative volunteers.Semantic proximity Read ↗

Adverse Neuropsychiatric Events and Recreational Use of Efavirenz and Other HIV-1 Antiretroviral DrugsSemantic proximity Read ↗

Paroxetine: population pharmacokinetic analysis in late-life depression using sparse concentration sampling.Semantic proximity Read ↗

Inhibition of metoprolol metabolism and potentiation of its effects by paroxetine in routinely treated patients with acute myocardial infarction (AMI).Semantic proximity Read ↗

Effect of smoking and CYP2D6 polymorphisms on the extent of fluvoxamine-alprazolam interaction in patients with psychosomatic disease.Semantic proximity Read ↗

Combination therapy with amprenavir, abacavir, and efavirenz in human immunodeficiency virus (HIV)-infected patients failing a protease-inhibitor regimen: pharmacokinetic drug interactions and antiviral activity.Semantic proximity Read ↗

Variations of CYP3A activity induced by antiretroviral treatment in HIV-1 infected patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.